Connect with us

Media OutReach

Johnson & Johnson launches The 3rd Opinion in Asia Pacific: a new term to elevate the patient voice in the lung cancer treatment journey

Published

6 months ago

on

  • Newly published research shows up to 77% of patients in Asia Pacific trust and rely on their physicians to decide their treatment for them despite 69% of physicians encouraging patients to engage in shared decision making1.
  • A new term, coined The 3rd Opinion, is designed to spark a social movement that empowers patients to recognize their vital role in shared decision-making, in a region that is disproportionately impacted by lung cancer2.

SINGAPORE –

According to newly published data on NSCLC patient preferences in Future Oncology, up to 77% of patients in Asia Pacific trust and rely on their physicians to decide their treatment for them despite 69% of physicians encouraging patients to engage in shared decision making[1]. Cultural norms around stigma, not questioning authority, and limited understanding of the disease can often be major barriers causing patients not to voice concerns or ask questions, even when healthcare professionals actively encourage their input.

“Being diagnosed with lung cancer is overwhelming. It’s natural for patients to seek clarity, often by pursuing a second opinion, to better understand their condition and treatment options. However, patients often hesitate to express their concerns and treatment goals, causing them to be overlooked in the decision-making process. By creating space for the patient’s own opinion, The 3rd Opinion, creates a new way of thinking about lung cancer treatment and empowers patients to find their voice,” said Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific.

J&J IM Key Visual Reunion The 3rd Opinion

Lung cancer has the highest incidence and mortality rate of all cancers worldwide, with more than 2.5 million people diagnosed every year, and Asia makes up 63% of all patients[2]. Up to 85% of lung cancers are non-small cell lung cancer (NSCLC) and Asians are more prone to certain genetic mutations than the rest of the world. One of the most prevalent is a mutation known as EGFR where 30-40% of all NSCLC diagnoses are in Asia, compared to 10-15% in the United States and Europe[3][4][5]. Often being diagnosed at a late stage, less than 20% of people with these genetic mutations survive beyond five years[6], and up to 40% never get the chance to receive a subsequent therapy after first-line treatment.[7][8][9]

“With the disproportionately high prevalence of certain NSCLC mutations in Asia Pacific, we need to think differently about how we treat patients and what more we can achieve with the first treatment. Treatment options have become increasingly complex and clinical decision making should comprehensively consider disease characteristics, patient treatment goals and values, and aim for an individualized balance between survival, longer lasting disease control and side effects. When shared decision making includes all available options, the final decision can be made collaboratively,” said Prof James Chih-Hsin Yang, Director of National Taiwan University Cancer Center and key advocate for The 3rd Opinion initiative.

J&J IM Key Visual Wedding The 3rd Opinion

Mark Brooke, Chief Executive Officer of Lung Foundation Australia, co-author of the Future Oncology publication and an advocate of The 3rd Opinion agreed, “The physician and patient dynamic is one of trust, but we cannot rely on that alone. The consequence is a potential disconnect between the patient and their healthcare professional around treatment preferences and personal goals. For patients, they often want more time above all else – to witness life’s milestones, more moments with loved ones, and more opportunities to simply live. Patients need to be equipped with adequate disease and treatment information, so they can communicate what matters most to them”.

J&J IM Key Visual Grandchild The 3rd Opinion

The 3rd Opinion will be launched across multiple markets with educational resources, including a Lung Cancer Book of Answers in China, a patient empowerment video and various shared decision making tools across Asia Pacific to spark a social movement that encourages patients to confidently articulate their personal goals for treatment. The creation of a neologism, like The 3rd Opinion, ensures shared decision making becomes accepted into clinical practice and in turn fosters an environment where the doctor’s expertise and the patient goals come together to design the best treatment plan.

[1] Chee Khoon Lee et al. Navigating advanced lung cancer care, patient–physician alliance, cancer stigma, and psychosocial support in Asia-Pacific: perspectives from patients, caregivers, and physicians. DOI: 10.1080/14796694.2025.2499511

[2] Natia Jokhadze MD, Arunangshu Das MBBS, Don S. Dizon MD. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Volume 74Issue 3CA: A Cancer Journal for Clinicians pages: 224-226 First Published online: April 4, 2024

[3] Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. Journal of Clinical Oncology. 2011; 29(15): 2121-2127.

[4] Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. Journal of Clinical Oncology. 2013; 66(2): 79-89.

[5] Korpanty G, et al. Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Frontiers in Oncology. 2014; 4: 204.

[6] Bazhenova L, Minchom A, Viteri S, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer. 2021;162:154-161.​

[7] Nieva J, Karia PS, Okhuoya P, et al. A real-world (rw) observational study of long-term survival (LTS) and treatment patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer [ESMO abstract 1344P]. Ann Oncol. 2023;34(suppl 2):S774 ​

[8] Lee JY, Mai V, Garcia M, et al. Treatment patterns and outcomes of first-line osimertinib-treated advanced EGFR mutated NSCLC patients: a real-world study [IASLC abstract EP08.02-082]. Presented at: IASLC 2022 World Lung Conference on Lung Cancer; August 6-9, 2022; Vienna, Austria.​

[9] Girard N, Leighl NB, Ohe Y, et al. Mortality among EGFR-mutated advanced NSCLC patients after starting frontline osimertinib treatment: a real-world, US attrition analysis. Presented at: the European Lung Cancer Congress; March 29-April 1, 2023; Copenhagen, Denmark. Poster 19P.​

Hashtag: #Johnson&Johnson

The issuer is solely responsible for the content of this announcement.

About The 3rd Opinion

“The 3rd Opinion”, the patients own opinion, is a new term that sparks a social movement in the lung cancer treatment journey – designed to elevate the patient voice and empower individuals to take an active role in shaping their treatment plan. By prioritizing shared decision-making between patients and healthcare professionals, this collaborative approach ensures that treatment choices are aligned to each patient’s goals, preferences and circumstances. This results in more informed decisions, greater patient satisfaction, and the best possible outcomes.

About Non-Small Cell Lung Cancer

Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.[10], [11] The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.[12] Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.[13] EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.[14], [15],[16],[17],[18],[19] EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.[20] The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent. [21], [22] EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.[23] Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.[24]By comparison, other common cancers, such as breast and prostate cancer have a 5-year real world OS of 90% and 97% respectively[25].

[10]The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[11] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[12] Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.

[13] Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[14] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[15] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[16] Pennell NA, et al. A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J Clin Oncol. 37:97-104.

[17] Burnett H, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[18] Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.

[19] Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911.

[20] American Lung Association. EGFR and Lung Cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr. Accessed March 2025.

[21] Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site.

[22] Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65

[23] Arcila, M. et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013 Feb; 12(2):220-9.

[24] Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[25] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, 2024.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more at or at . Follow us at .

Related Topics:
Advertisement

Media OutReach

VF 8 Is Connecting a New Global VinFast Community

Published

2 days ago

on

16/01/2026

By

VinFast’s electric SUV is earning loyalty from Vietnam to the Middle East by fitting seamlessly into real lives, long drives, and daily routines.

HAI PHONG, VIETNAM – Media OutReach Newswire – 16 January 2026 – VinFast’s VF 8 is traveling well, winning over drivers across markets with everyday performance, thoughtful design, and uncommon peace of mind.

A VF 8 owner belong to a relatively exclusive, self-selecting club that its maker VinFast have built across the globe. It is the kind of club formed less by marketing than by shared curiosity and a willingness to move early. Owners tend to recognize one another not by badges or decals, but by the confidence that comes from having made a deliberate choice.

The VF 8 holds a special place for VinFast. It was the brand’s first fully international offering, the vehicle tasked with introducing a young Vietnamese automaker to demanding markets abroad. As a result, the car was designed to travel well. Styled in collaboration with Pininfarina, the VF 8 favors clean proportions over visual noise. Beneath the surface, its dual-motor all-wheel-drive system and 402 horsepower provide performance that feels reassuring.

In Vietnam, the VF 8 has appealed to high-mileage drivers like Nguyen Phuong Hoang Dung, a Ho Chi Minh City-based construction project manager who covers about 5,000 kilometers a month. “When you drive that much, comfort and stability directly affect your health, your mindset, and how well you work,” he said. Having spent years with gasoline cars, he switched to the VF 8 in August 2025, drawn by its smooth throttle response and calm, seamless acceleration. Now, with more than 20,000 kilometers behind him, he said, “The more I drive it, the more confident I am that choosing the VF 8 was the right decision.”

As the VF 8 expanded into North America and Europe, it increasingly settled into a simpler role: a dependable everyday vehicle. Robert, who has driven his for more than a year and a half, said it has been “a great vehicle,” adding that “you will not find another this size in the price range they offered it.” For Jonathan, the VF 8 fits neatly into daily routines. “For us it’s a city vehicle with short rides every day, and it answers our needs,” he said. “Very comfortable, impressive performance, good in snow, and strong overall.”

In the Middle East, the VF 8’s appeal sharpens as VinFast pairs the car with ownership benefits that are rare in the segment, including complimentary maintenance coverage for five years or 100,000 kilometers. These are not small details in markets where peace of mind often matters as much as design. “The maintenance package made the decision easy,” said an owner in Dubai. “You know exactly where you stand.”

The idea of a VF 8 community is beginning to take shape. Across markets, it connects drivers in Vietnam, Europe, North America, and the Middle East through a shared understanding of what modern electric ownership can be. Thoughtful design. Capable performance. A clear push toward sustainability without asking drivers to compromise their routines.

For those inside the club, the VF 8 is not simply a statement car. No, something even better. A car that makes sense, day after day, in very different parts of the world.

Hashtag: #VF8 #VinFast

The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

ONYX Hospitality Group Partners with Yee Fung Group to Launch “Y Hotel Nanshan Shenzhen”, Expanding its Portfolio in China

Published

2 days ago

on

16/01/2026

By

BANGKOK, THAILAND – Media OutReach Newswire – 16 January 2026 – ONYX Hospitality Group, a leading Southeast Asian hospitality management company specialising in hotels, resorts, serviced apartments, and luxury residences, is proud to announce its new partnership with Yee Fung Group to operate Y Hotel Nanshan in Shenzhen, People’s Republic of China.

ONYX Hospitality Group oversees renowned brands including Amari, OZO, Shama, and Oriental Residence across key destinations in the Asia–Pacific region. This agreement marks another significant milestone in strengthening ONYX’s presence in the Chinese market. Scheduled to open in Q4 2026, the hotel supports ONYX’s long-term growth strategy as it works toward its target of managing more than 75 properties by 2030.

Mr Yuthachai Charanachitta, Chief Executive Officer of ONYX Hospitality Group, commented: “This collaboration reflects the strong confidence Yee Fung Group has in ONYX, following our successful partnership in managing Y Hotel Hong Kong. It represents a significant step forward in building on that success and further expanding ONYX’s presence in the Greater China market. At the same time, this partnership reinforces ONYX’s position as a distinctive ‘Regional Player’, well-positioned for stable and sustainable growth across the region.”

Y Hotel Nanshan Shenzhen featuring 82 thoughtfully designed guest rooms and suites, located within YEE FUNG PLACE on a strategically significant site surrounded by key national infrastructure. The area is supported by five major national sea and land ports, including Shekou, Chiwan and Mawan, servicing more than 150 shipping routes. It is also situated at the heart of one of China’s leading innovation and industrial hubs, home to sectors such as integrated circuits, artificial intelligence, biomedicine and the marine economy, alongside more than 50 specialised industrial parks.

Y Hotel Nanshan Shenzhen is ideally suited for leisure travellers, offering convenient accessibility just 35 minutes from Shenzhen Baoan International Airport and 31 minutes from Shenzhen North Railway Station, and only 650 metres from Lilin Subway Station. The surrounding area features vibrant food markets and nightlife destinations such as Nanyi Fang, Shekou Sea World, Green World and Houhai, as well as cultural and recreational attractions including Shenzhen Poly Theatre, Shenzhen Talent Park, Nanshan Museum, Nanshan Park and Shenzhen Bay Park. Guests will also find leading shopping centres nearby, including Walmart, Xinhe Shopping Plaza, Garden City, Haiya Mega Mall, Coastal City and Shenzhen Bay MixC.

Furthermore, the hotel is located close to the headquarters of major national technology companies such as ZTE, Tencent, Huawei, Alibaba, Han’s Laser and Mindray, as well as Shenzhen University, positioning it as both a relaxing retreat and a strategic hub for business travellers seeking comfort alongside a distinctive lifestyle experience.Hashtag: #ONYXHospitalityGroup #YeeFungGroup #YHotel #HospitalityManagement #HotelManagement #LifestyleHotel



The issuer is solely responsible for the content of this announcement.

About ONYX Hospitality Group:

ONYX Hospitality Group, a reputable force in Southeast Asia’s hospitality industry, operates a collection of comprehensive yet complementary brands – Amari, OZO, Shama and Oriental Residence – catering to the distinctive needs of discerning business and leisure travellers in Southeast Asia where their expertise lies. In addition to its brand portfolio, ONYX Hospitality Group also operates additional hospitality services across spa and food and beverage. With over five decades of management experience, the company extends its innovative solutions throughout the region, upholding internationally recognised standards and ensuring optimal operational manoeuvrability. By fostering enduring relationships with like-minded business partners, ONYX Hospitality Group delivers unparalleled experiences in a dynamic and competitive market, meeting the ever-evolving demands of travellers.

More information:

Continue Reading

Media OutReach

AFERIY Unveils Next-Generation Portable Power Station Nomad1800 at CES

Published

3 days ago

on

16/01/2026

By

LAS VEGAS, US – Media OutReach Newswire – 16 January 2026 – As the Consumer Electronics Show (CES) 2026 officially opened, AFERIY, an innovative global brand in the portable clean energy sector, announced the launch of its next-generation portable power station, the Nomad1800, drawing widespread attention from industry professionals and the media.

More Compact Size, Greater Power Output

The AFERIY Nomad1800 keeps the same battery capacity while boosting power output by 50% through system and structural optimization. Weighing 11.6 kg, it is about 10% lighter than the previous model.

Despite its lighter design, it delivers 1800 W rated AC output (peak 3600 W), powering appliances like rice cookers, kettles, car refrigerators, and induction cooktops for camping, RVs, and home emergencies.

Fast Charging: 0–80% in 36 Minutes

The Nomad1800 adopts a hybrid fast-charging solution supporting both AC grid power and solar input. It can charge from 0% to 80% in just 36 minutes, significantly reducing charging time. This fast-charging capability allows the Nomad1800 to adapt to short stops, travel intervals, and unexpected power outages, providing users with efficient and predictable energy support.

Safe and Durable LiFePO₄ Battery

The Nomad1800 is equipped with a 1024 Wh lithium iron phosphate (LiFePO₄) battery supplied by EVE Energy. After more than 4,000 charge and discharge cycles, the battery retains up to 80% of its capacity.

An intelligent BMS monitors voltage, current, and temperature to ensure safe, stable operation even under high load or fast charging.

Industry-Leading Seven-Year Warranty

AFERIY offers the Nomad1800 an industry-leading seven-year warranty on core components and systems, reflecting confidence in its quality, safety, and durability.

Comprehensive Power and Safety Protection

The Nomad1800 features multiple output ports, enabling simultaneous power supply to multiple devices. It also supports UPS functionality, switching within 10 milliseconds during grid power interruptions to protect sensitive equipment such as computers and routers.

Under low-load operation, noise levels remain below 30 dB. In addition, the unit includes built-in LED lighting and an SOS flashing mode to enhance safety during nighttime and emergency use.

For more information, please visit the official AFERIY website or AFERIY on Amazon.

Hashtag: #AFERIY

The issuer is solely responsible for the content of this announcement.

About AFERIY

AFERIY is a global brand focused on portable energy storage and clean energy solutions, committed to providing efficient, safe, and reliable power for outdoor activities, home emergency use, and professional applications.

Continue Reading

Trending